As shown in Figure 3C-3E, both the compounds stimulated CARP-1 expression, activation of SAPKs, PARP cleavage, and loss of cyclin B1 in the Everolimus-resistant UOK262 and A498 RCC cells. The gene discussed is PARP1; the disease is renal cell carcinoma.